S&P 500   3,622.71 (-0.49%)
DOW   28,992.52 (-0.80%)
QQQ   270.46 (-0.52%)
AAPL   140.34 (-1.50%)
MSFT   235.84 (-0.70%)
META   137.18 (+0.56%)
GOOGL   96.84 (-0.60%)
AMZN   114.89 (+0.08%)
TSLA   267.72 (-0.18%)
NVDA   122.99 (+0.65%)
NIO   15.77 (+1.22%)
BABA   80.48 (+1.80%)
AMD   64.17 (+0.05%)
T   15.42 (-0.71%)
MU   50.97 (+1.92%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.54 (-0.30%)
DIS   95.83 (-1.66%)
AMC   7.13 (+0.42%)
PYPL   87.14 (-1.76%)
PFE   44.24 (+0.18%)
NFLX   239.72 (+0.00%)
S&P 500   3,622.71 (-0.49%)
DOW   28,992.52 (-0.80%)
QQQ   270.46 (-0.52%)
AAPL   140.34 (-1.50%)
MSFT   235.84 (-0.70%)
META   137.18 (+0.56%)
GOOGL   96.84 (-0.60%)
AMZN   114.89 (+0.08%)
TSLA   267.72 (-0.18%)
NVDA   122.99 (+0.65%)
NIO   15.77 (+1.22%)
BABA   80.48 (+1.80%)
AMD   64.17 (+0.05%)
T   15.42 (-0.71%)
MU   50.97 (+1.92%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.54 (-0.30%)
DIS   95.83 (-1.66%)
AMC   7.13 (+0.42%)
PYPL   87.14 (-1.76%)
PFE   44.24 (+0.18%)
NFLX   239.72 (+0.00%)
S&P 500   3,622.71 (-0.49%)
DOW   28,992.52 (-0.80%)
QQQ   270.46 (-0.52%)
AAPL   140.34 (-1.50%)
MSFT   235.84 (-0.70%)
META   137.18 (+0.56%)
GOOGL   96.84 (-0.60%)
AMZN   114.89 (+0.08%)
TSLA   267.72 (-0.18%)
NVDA   122.99 (+0.65%)
NIO   15.77 (+1.22%)
BABA   80.48 (+1.80%)
AMD   64.17 (+0.05%)
T   15.42 (-0.71%)
MU   50.97 (+1.92%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.54 (-0.30%)
DIS   95.83 (-1.66%)
AMC   7.13 (+0.42%)
PYPL   87.14 (-1.76%)
PFE   44.24 (+0.18%)
NFLX   239.72 (+0.00%)
S&P 500   3,622.71 (-0.49%)
DOW   28,992.52 (-0.80%)
QQQ   270.46 (-0.52%)
AAPL   140.34 (-1.50%)
MSFT   235.84 (-0.70%)
META   137.18 (+0.56%)
GOOGL   96.84 (-0.60%)
AMZN   114.89 (+0.08%)
TSLA   267.72 (-0.18%)
NVDA   122.99 (+0.65%)
NIO   15.77 (+1.22%)
BABA   80.48 (+1.80%)
AMD   64.17 (+0.05%)
T   15.42 (-0.71%)
MU   50.97 (+1.92%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.54 (-0.30%)
DIS   95.83 (-1.66%)
AMC   7.13 (+0.42%)
PYPL   87.14 (-1.76%)
PFE   44.24 (+0.18%)
NFLX   239.72 (+0.00%)
NYSE:TEVA

Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

$8.13
+0.31 (+3.96%)
(As of 09/30/2022 02:09 PM ET)
Add
Compare
Today's Range
$7.81
$8.23
50-Day Range
$7.01
$11.21
52-Week Range
$6.78
$11.34
Volume
335,673 shs
Average Volume
8.64 million shs
Market Capitalization
$9.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
30.9% Upside
$10.67 Price Target
Short Interest
Healthy
2.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.08 M Sold Last Quarter
Proj. Earnings Growth
-1.23%
From $2.44 to $2.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

904th out of 1,097 stocks

Pharmaceutical Preparations Industry

447th out of 548 stocks

TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

Adderall Shortages Push ADHD Patients to Make Adjustments
Teva- Pharmaceutical Industries Ltd. - ADR
Teva Pharmaceutical Industries Ltd (TEVA)
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Company Calendar

Last Earnings
7/26/2022
Today
9/30/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
37,537
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+31.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$417 million
Pretax Margin
-12.47%

Debt

Sales & Book Value

Annual Sales
$15.88 billion
Cash Flow
$3.76 per share
Book Value
$10.19 per share

Miscellaneous

Outstanding Shares
1,110,560,000
Free Float
1,101,458,000
Market Cap
$9.03 billion
Optionable
Optionable
Beta
1.27

Key Executives

  • Mr. Kare Schultz (Age 61)
    Pres, CEO & Director
    Comp: $4.68M
  • Mr. Eliyahu Sharon Kalif (Age 49)
    Exec. VP & CFO
    Comp: $1.74M
  • Mr. Eric  DrapeMr. Eric Drape (Age 60)
    Exec. VP of Global Operations
    Comp: $1.91M
  • Mr. Mark  SabagMr. Mark Sabag (Age 51)
    Exec. VP of International Markets Commercial
    Comp: $1.79M
  • Dr. Sven Dethlefs Ph.D. (Age 53)
    Exec. VP of North America Commercial
    Comp: $1.72M
  • Mr. Amir Weiss (Age 45)
    Sr. VP & Chief Accounting Officer
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations
  • Mr. David M. Stark (Age 53)
    Exec. VP & Chief Legal Officer
  • Kathleen Veit
    Sr. VP, Global Compliance & Ethics Officer
  • Mr. Eli  ShaniMr. Eli Shani
    Exec. VP of Global Marketing & Portfolio













TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2022?

8 brokers have issued twelve-month price objectives for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2022?

Teva Pharmaceutical Industries' stock was trading at $8.01 at the start of the year. Since then, TEVA shares have decreased by 2.4% and is now trading at $7.82.
View the best growth stocks for 2022 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a increase in short interest in September. As of September 15th, there was short interest totaling 25,940,000 shares, an increase of 28.0% from the August 31st total of 20,270,000 shares. Based on an average daily trading volume, of 13,920,000 shares, the days-to-cover ratio is presently 1.9 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our TEVA earnings forecast
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its earnings results on Tuesday, July, 26th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.09. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.82 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 25.68% and a negative net margin of 6.83%.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $2.40-$2.60 for the period. The company issued revenue guidance of $15.00 billion-$15.60 billion, compared to the consensus revenue estimate of $15.67 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $7.82.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $8.68 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 37,537 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.